BeiGene Price to Sales Ratio 2014-2024 | ONC
Historical PS ratio values for BeiGene (ONC) over the last 10 years. The current P/S ratio for BeiGene as of January 03, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| BeiGene P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2025-01-03 |
180.82 |
|
5.72 |
| 2024-09-30 |
224.51 |
$31.62 |
7.10 |
| 2024-06-30 |
142.67 |
$29.47 |
4.84 |
| 2024-03-31 |
156.39 |
$26.28 |
5.95 |
| 2023-12-31 |
180.36 |
$23.37 |
7.72 |
| 2023-09-30 |
179.87 |
$20.98 |
8.57 |
| 2023-06-30 |
178.30 |
$17.42 |
10.24 |
| 2023-03-31 |
215.53 |
$15.05 |
14.32 |
| 2022-12-31 |
219.94 |
$13.75 |
16.00 |
| 2022-09-30 |
134.82 |
$12.37 |
10.90 |
| 2022-06-30 |
161.85 |
$10.85 |
14.92 |
| 2022-03-31 |
188.60 |
$9.16 |
20.60 |
| 2021-12-31 |
270.93 |
$12.43 |
21.80 |
| 2021-09-30 |
363.00 |
$11.32 |
32.06 |
| 2021-06-30 |
343.19 |
$10.13 |
33.89 |
| 2021-03-31 |
348.08 |
$9.34 |
37.28 |
| 2020-12-31 |
258.39 |
$3.75 |
68.95 |
| 2020-09-30 |
286.44 |
$3.50 |
81.94 |
| 2020-06-30 |
188.40 |
$3.30 |
57.10 |
| 2020-03-31 |
123.11 |
$6.52 |
18.87 |
| 2019-12-31 |
165.76 |
$7.16 |
23.16 |
| 2019-09-30 |
122.46 |
$7.27 |
16.85 |
| 2019-06-30 |
123.95 |
$7.39 |
16.78 |
| 2019-03-31 |
132.00 |
$4.30 |
30.70 |
| 2018-12-31 |
140.26 |
$3.62 |
38.70 |
| 2018-09-30 |
172.22 |
$3.00 |
57.38 |
| 2018-06-30 |
153.73 |
$6.82 |
22.56 |
| 2018-03-31 |
168.00 |
$5.83 |
28.80 |
| 2017-12-31 |
97.72 |
$5.20 |
18.79 |
| 2017-09-30 |
103.46 |
$4.77 |
21.71 |
| 2017-06-30 |
45.00 |
0 |
0.00 |
| 2017-03-31 |
36.61 |
$0.01 |
3065.18 |
| 2016-12-31 |
30.36 |
$0.04 |
725.02 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
